ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024
The Paradox of Poor Cervical Cancer Screening Uptake for Kidney Transplant Recipients.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplant recipients have an increased risk for developing and dying from cervical cancer compared with the general population due to their immunosuppressed state. As one of the cancers most amenable to an effective screening program, encouraging eligible women after transplantation to adhere to screening is critically important. Therefore, the observation that kidney transplant recipients may have a lower uptake of cervical cancer screening compared with the general population is concerning. The reasons for this should be studied so that any barriers can be identified and overcome. Kidney transplant recipients and recipients of other solid organ allografts must be encouraged and supported to adhere to recommended screening programs to mitigate the morbidity and mortality of posttransplantation cancer. See related article by Hsu et al., p. 1678.
Indexed as
Identifiers
39618255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.